Newly Diagnosed Dyslipidemia Patients Do Not Receive Any Drug Treatment In First Year
Decision Resources finds that 78% of newly diagnosed dyslipidemia patients do not receive any drug treatment in the first year of diagnosis.
According to the new report entitled Treatment Algorithms in Dyslipidemia, failure of newly diagnosed dyslipidemia patients to receive pharmacological treatment within the first 12 months of diagnosis likely occurs as a result of physicians' and patients' attempts to control the disease through diet and exercise. Furthermore, because the NCEP ATP III guidelines do not define specific time periods for when treatment should be initiated, patients may be reluctant to begin chronic pharmacotherapy for an asymptomatic disease.
The report also finds that Pfizer's Lipitor remains the most popular first-line statin for the treatment of dyslipidemia.
"Of all newly diagnosed dyslipidemia patients, 75.4% are prescribed a statin; 40.5% and 13.7% of patients, respectively, receive Lipitor and simvastatin first-line," said Saema Magre, analyst at Decision Resources. "Patients not on statins may be statin-intolerant or suffering from elevated levels of lipids other than LDL. Lipitor is by far the most popular statin, as a result of its efficacy in regard to LDL-lowering and its backing by strong clinical trial evidence."
Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.
For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides:
-- Summary of U.S. medical practice based on interviews with leading experts in the field
-- Qualitative diagnosis/referral/treatment algorithm for the United States
-- Drug usage by lines of therapy (1st, 2nd, 3rd line)
-- Discussion of key freeform combinations by lines of therapy
-- Product share (class and specific compound level) within each line of therapy (1st, 2nd, 3rd line)
-- Progression of therapy from key 1st line products
-- Pathway to key therapies from previous therapies
-- Qualitative analysis of 2-year forecast incorporating upcoming launches, changes in reimbursement, etc.